Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167553 · ClinicalTrials.gov registry record · Phase 1
Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities
A Phase 1 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT04167553 is a Phase 1 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 52 participants.
The verdict
NCT04167553, a Phase 1 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.
Interventions
- DRUG Placebo
- DRUG HM15136
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2019-08-30 |
| Est. Completion | 2020-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04167553
The ClinicalTrials.gov registry entry for NCT04167553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04167553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04167553 about?
NCT04167553 is a clinical study titled "Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities". The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.
What is the current status of trial NCT04167553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2019-08-30. Estimated completion is 2020-12-09.
What interventions are being tested in trial NCT04167553?
The interventions under investigation include: Placebo (DRUG), HM15136 (DRUG).
Who is sponsoring clinical trial NCT04167553?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.